TGF-β1 levels are apparently boosted in colon, esophageal, gastric, hepatocellular and pancreatic cancer; and correlate with tumor progression, metastasis and angiogenesis, which result in poor prognostic outcome [4]. This evidence concerns the gene TGFB1 and neoplasm.